Last Friday, a spinoff we’ve written about several times became a reality. Harvard Biosciences (HBIO) spun off Harvard Apparatus Regenerative Technologies(HART) to shareholders. HBIO shareholders received one share of HART for every four shares of HBIO owned. With management going to the spin off, recently appointed HBIO CEO Jeffery A. Duchemin received the additional titles of President and… Read More »
Harvard Bioscience Inc’s (HBIO) board of directors approved the spinoff of its regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology. The spin is set to take place on November 1st with HBIO shareholders receiving 1 share of the new company for every 4 shares of HBIO owned. The new company will trade under the ticker ‘HART’ and a when… Read More »
What does it take to get into Harvard? Around $4, plus commission. Massachusetts-based Harvard Bioscience(HBIO) has long been a leading manufacturer of apparatus and scientific equipment, but, with a market capitalization of just $115 million, it has flown under the radar of many investors. Founded in the basement of Harvard Medical School in 1901 by Dr. William T.… Read More »